Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ESC Congress

Discover the latest news and 2024 updates on managing hypertension, heart failure, coronary syndromes, atrial fibrillation and arterial disease. 
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in:

18-12-2023 | Atrial Fibrillation | Review

Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity

Authors: Krunal Amin, Garrett Bethel, Larry R. Jackson II, Utibe R. Essien, Caroline E. Sloan

Published in: Current Atherosclerosis Reports | Issue 12/2023

Login to get access

Abstract

Purpose of Review

Pharmacoequity refers to the goal of ensuring that all patients have access to high-quality medications, regardless of their race, ethnicity, gender, or other characteristics. The goal of this article is to review current evidence on disparities in access to cardiovascular drug therapies across sociodemographic subgroups, with a focus on heart failure, atrial fibrillation, and dyslipidemia.

Recent Findings

Considerable and consistent disparities to life-prolonging heart failure, atrial fibrillation, and dyslipidemia medications exist in clinical trial representation, access to specialist care, prescription of guideline-based therapy, drug affordability, and pharmacy accessibility across racial, ethnic, gender, and other sociodemographic subgroups.

Summary

Researchers, health systems, and policy makers can take steps to improve pharmacoequity by diversifying clinical trial enrollment, increasing access to inpatient and outpatient cardiology care, nudging clinicians to increase prescription of guideline-directed medical therapy, and pursuing system-level reforms to improve drug access and affordability.
Literature
1.
Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93–621.PubMedCrossRef
2.
Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933–44.PubMedCrossRef
3.
Chiang CE, Naditch-Brule L, Murin J, Goethals M, Inoue H, O’Neill J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol. 2012;5(4):632–9.PubMedCrossRef
4.
5.
Mohebi R, Chen C, Ibrahim NE, McCarthy CP, Gaggin HK, Singer DE, et al. Cardiovascular disease projections in the United States Based on the 2020 census estimates. J Am Coll Cardiol. 2022;80(6):565–78.PubMedPubMedCentralCrossRef
6.
LaRosa AR, Claxton J, O’Neal WT, Lutsey PL, Chen LY, Bengtson L, et al. Association of household income and adverse outcomes in patients with atrial fibrillation. Heart. 2020;106(21):1679–85.PubMedCrossRef
7.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: Executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):1757–80.PubMedCrossRef
8.
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–51.PubMedCrossRef
9.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143.PubMed
10.
Piccini JP, Allred J, Bunch TJ, Deering TF, Di Biase L, Hussein AA, et al. Rationale, considerations, and goals for atrial fibrillation centers of excellence: a Heart Rhythm Society perspective. Heart Rhythm. 2020;17(10):1804–32.PubMedCrossRef
11.
Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305–16.PubMedCrossRef
12.
Committee W, Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, et al. 2022 ACC Expert Consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(14):1366–418.CrossRef
13.
Hussain A, Ramsey D, Lee M, Mahtta D, Khan MS, Nambi V, et al. Utilization rates of SGLT2 inhibitors among patients with type 2 diabetes, heart failure, and atherosclerotic cardiovascular disease: insights from the Department of Veterans Affairs. JACC Heart Fail. 2023;11(8 Pt 1):933–42.PubMedCrossRef
14.
Tran JS, Loveland MG, Alamer A, Piña IL, Sweitzer NK. Clinical and socioeconomic determinants of angiotensin receptor-neprilysin inhibitor prescription at hospital discharge in patients with heart failure with reduced ejection fraction. Circ Heart Fail. 2022;15(11):e009395.PubMedPubMedCentralCrossRef
15.
Witting C, Zheng J, Tisdale RL, Shannon E, Kohsaka S, Lewis EF, et al. Treatment differences in medical therapy for heart failure with reduced ejection fraction between sociodemographic groups. JACC Heart Fail. 2023;11(2):161–72.PubMedCrossRef
16.
Eberly LA, Yang L, Eneanya ND, Essien U, Julien H, Nathan AS, et al. Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US. JAMA Netw Open. 2021;4(4):e216139.PubMedPubMedCentralCrossRef
17.
Tromp J, Ezekowitz JA, Ouwerkerk W, Chandramouli C, Yiu KH, Angermann CE, et al. Global Variations according to sex in patients hospitalized for heart failure in the REPORT-HF Registry. JACC Heart Fail. 2023;11(9):1262–71.PubMedCrossRef
18.
Essien UR, Holmes DN, Jackson LR, Fonarow GC, Mahaffey KW, Reiffel JA, et al. Association of race/ethnicity with oral anticoagulant use in patients with atrial fibrillation: findings from the outcomes registry for better informed treatment of atrial fibrillation II. JAMA Cardiol. 2018;3(12):1174–82.PubMedPubMedCentralCrossRef
19.
Essien UR, Kim N, Magnani JW, Good CB, Litam TMA, Hausmann LRM, et al. Association of race and ethnicity and anticoagulation in patients with atrial fibrillation dually enrolled in Veterans Health Administration and Medicare: effects of medicare part D on prescribing disparities. Circ Cardiovasc Qual Outcomes. 2022;15(2):e008389.PubMedCrossRef
20.
Essien UR, Kim N, Hausmann LRM, Mor MK, Good CB, Magnani JW, et al. Disparities in anticoagulant therapy initiation for incident atrial fibrillation by race/ethnicity among patients in the Veterans Health Administration System. JAMA Netw Open. 2021;4(7):e2114234.PubMedPubMedCentralCrossRef
21.
Yong CM, Tremmel JA, Lansberg MG, Fan J, Askari M, Turakhia MP. Sex differences in oral anticoagulation and outcomes of stroke and intracranial bleeding in newly diagnosed atrial fibrillation. J Am Heart Assoc. 2020;9(10):e015689.PubMedPubMedCentralCrossRef
22.
McDermott A, Kim N, Hausmann LRM, Magnani JW, Good CB, Litam TMA, et al. Association of neighborhood disadvantage and anticoagulation for patients with atrial fibrillation in the Veterans Health Administration: the REACH-AF Study. J Gen Intern Med. 2023;38(4):848–56.PubMedCrossRef
23.
Jackson LR II, Friedman DJ, Francis DM, Maccioni S, Thomas VC, Coplan P, et al. Race and ethnic and sex differences in rhythm control treatment of incident atrial fibrillation. Clinicoecon Outcomes Res. 2023;15:387–95.CrossRef
24.
Minhas AMK, Ijaz SH, Javed N, Sheikh AB, Jain V, Michos ED, et al. National trends and disparities in statin use for ischemic heart disease from 2006 to 2018: Insights from National Ambulatory Medical Care Survey. Am Heart J. 2022;252:60–9.PubMedCrossRef
25.
Nanna MG, Navar AM, Zakroysky P, Xiang Q, Goldberg AC, Robinson J, et al. Association of Patient perceptions of cardiovascular risk and beliefs on statin drugs with racial differences in statin use: insights from the patient and provider assessment of Lipid Management Registry. JAMA Cardiol. 2018;3(8):739–48.PubMedPubMedCentralCrossRef
26.
Navar AM, Kolkailah AA, Gupta A, Gillard KK, Israel MK, Wang Y, et al. Gaps in guideline-based lipid-lowering therapy for secondary prevention in the United States: a retrospective cohort study of 322 153 patients. Circ Cardiovasc Qual Outcomes. 2023;16(8):533–43.PubMedCrossRef
27.
Frank DA, Johnson AE, Hausmann LRM, Gellad WF, Roberts ET, Vajravelu RK. Disparities in guideline-recommended statin use for prevention of atherosclerotic cardiovascular disease by race, ethnicity, and gender : a nationally representative cross-sectional analysis of adults in the United States. Ann Intern Med. 2023;176(8):1057–66.PubMedCrossRef
28.
Gamboa CM, Colantonio LD, Brown TM, Carson AP, Safford MM. Race-Sex differences in statin use and low-density lipoprotein cholesterol control among people with diabetes mellitus in the Reasons for Geographic and Racial Differences in Stroke Study. J Am Heart Assoc. 2017;6(5).
29.
Robinson JG, Booth B. Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. J Clin Lipidol. 2010;4(6):483–90.PubMedPubMedCentralCrossRef
30.
Yao X, Shah ND, Gersh BJ, Lopez-Jimenez F, Noseworthy PA. Assessment of trends in statin therapy for secondary prevention of atherosclerotic cardiovascular disease in US adults from 2007 to 2016. JAMA Netw Open. 2020;3(11):e2025505.PubMedPubMedCentralCrossRef
31.
Kyalwazi AN, Loccoh EC, Brewer LC, Ofili EO, Xu J, Song Y, et al. Disparities in cardiovascular mortality between black and white adults in the United States, 1999 to 2019. Circulation. 2022;146(3):211–28.PubMedPubMedCentralCrossRef
32.
Rao VN, Mentz RJ, Coniglio AC, Kelsey MD, Fudim M, Fonarow GC, et al. Neighborhood socioeconomic disadvantage and hospitalized heart failure outcomes in the American Heart Association get with the Guidelines-Heart Failure Registry. Circ Heart Fail. 2022;15(11):e009353.PubMedPubMedCentralCrossRef
33.
Akwo EA, Kabagambe EK, Wang TJ, Harrell FE, Jr., Blot WJ, Mumma M et al. Heart failure incidence and mortality in the southern community cohort study. Circ Heart Fail. 2017;10(3).
34.
Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol. 2008;101(7):1016–22.PubMedCrossRef
35.
36.
Magnani JW, Norby FL, Agarwal SK, Soliman EZ, Chen LY, Loehr LR, et al. Racial differences in atrial fibrillation-related cardiovascular disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. JAMA Cardiol. 2016;1(4):433–41.PubMedPubMedCentralCrossRef
37.
Ugowe FE, Jackson LR, Thomas KL. Racial and ethnic differences in the prevalence, management, and outcomes in patients with atrial fibrillation: a systematic review. Heart Rhythm. 2018;15(9):1337–45.PubMedCrossRef
38.
Tertulien T, Chen Y, Althouse AD, Essien UR, Johnson A, Magnani JW. Association of income and educational attainment in hospitalization events in atrial fibrillation. Am J Prev Cardiol. 2021;7:100201.PubMedPubMedCentralCrossRef
39.
Loccoh EC, Joynt Maddox KE, Wang Y, Kazi DS, Yeh RW, Wadhera RK. Rural-urban disparities in outcomes of myocardial infarction, heart failure, and stroke in the United States. J Am Coll Cardiol. 2022;79(3):267–79.PubMedPubMedCentralCrossRef
40.
Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical Therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry. J Am Coll Cardiol. 2018;72(4):351–66.PubMedCrossRef
41.
Mwansa H, Lewsey S, Mazimba S, Breathett K. Racial/ethnic and gender disparities in heart failure with reduced ejection fraction. Curr Heart Fail Rep. 2021;18(2):41–51.PubMedPubMedCentralCrossRef
42.
43.
Chalasani R, Krishnamurthy S, Suda KJ, Newman TV, Delaney SW, Essien UR. Pursuing pharmacoequity: determinants, drivers, and pathways to progress. J Health Polit Policy Law. 2022;47(6):709–29.PubMedCrossRef
44.
•• Essien UR, Dusetzina SB, Gellad WF. A policy prescription for reducing health disparities-achieving pharmacoequity. JAMA. 2021;326(18):1793–4. This editorial coined the term "pharmacoequity" as the goal of "ensuring that all individuals, regardless of race and ethnicity, socioeconomic status, or availability of resources, have access to the highest-quality medications required to manage their health needs is paramount." It inspired the development of a framework that clinicians and researchers can use to understand disparities in access to pharmacotherapy and to develop strategies for achieving pharmacoequity (see reference #42).PubMedCrossRef
45.
Reza N, Gruen J, Bozkurt B. Representation of women in heart failure clinical trials: barriers to enrollment and strategies to close the gap. Am Heart J Plus. 2022;13.
46.
Cho L, Vest AR, O’Donoghue ML, Ogunniyi MO, Sarma AA, Denby KJ, et al. Increasing participation of women in cardiovascular trials: JACC Council Perspectives. J Am Coll Cardiol. 2021;78(7):737–51.PubMedCrossRef
47.
Essien UR, Kornej J, Johnson AE, Schulson LB, Benjamin EJ, Magnani JW. Social determinants of atrial fibrillation. Nat Rev Cardiol. 2021;18(11):763–73.PubMedPubMedCentralCrossRef
48.
Khan MZ, Munir MB, Khan SU, Subramanian CR, Khan MU, Asad ZUA, et al. Representation of women, older patients, ethnic, and racial minorities in trials of atrial fibrillation. Pacing Clin Electrophysiol. 2021;44(3):423–31.PubMedPubMedCentralCrossRef
49.
Noubiap JJ, Thomas G, Nyaga UF, Fitzgerald JL, Gallagher C, Middeldorp ME, et al. Sex disparities in enrollment and reporting of outcomes by sex in contemporary clinical trials of atrial fibrillation. J Cardiovasc Electrophysiol. 2022;33(5):845–54.PubMedPubMedCentralCrossRef
50.
• DeFilippis EM, Echols M, Adamson PB, Batchelor WB, Cooper LB, Cooper LS, et al. Improving enrollment of underrepresented racial and ethnic populations in heart failure trials: a call to action from the heart failure collaboratory. JAMA Cardiol. 2022;7(5):540–8. This article provides and in-depth review of the causes of lack of diversity in HF trial enrollment and concrete strategies for improving representation moving forward. While it is focused on a single disease (HF), the lessons it puts forth can be extrapolated to other cardiovascular diseases including HF and dyslipidemia.PubMedPubMedCentralCrossRef
51.
Scott PE, Unger EF, Jenkins MR, Southworth MR, McDowell TY, Geller RJ, et al. Participation of women in clinical trials supporting FDA approval of cardiovascular drugs. J Am Coll Cardiol. 2018;71(18):1960–9.PubMedCrossRef
52.
Chen S, Li J. Participation of Black US residents in clinical trials of 24 cardiovascular drugs granted FDA approval, 2006–2020. JAMA Netw Open. 2021;4(3):e212640.PubMedPubMedCentralCrossRef
53.
Ortega RF, Yancy CW, Mehran R, Batchelor W. Overcoming lack of diversity in cardiovascular clinical trials: a new challenge and strategies for success. Circulation. 2019;140(21):1690–2.PubMedCrossRef
54.
Taylor AL. The African American Heart Failure Trial: a clinical trial update. Am J Cardiol. 2005;96(7B):44–8.PubMedCrossRef
55.
Taylor AL, Lindenfeld J, Ziesche S, Walsh MN, Mitchell JE, Adams K, et al. Outcomes by gender in the African-American Heart Failure Trial. J Am Coll Cardiol. 2006;48(11):2263–7.PubMedCrossRef
56.
McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation. 2020;141(5):338–51.PubMedCrossRef
57.
Tahhan AS, Vaduganathan M, Greene SJ, Fonarow GC, Fiuzat M, Jessup M, et al. Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: a systematic review. JAMA Cardiol. 2018;3(10):1011–9.PubMedCrossRef
58.
Wei S, Le N, Zhu JW, Breathett K, Greene SJ, Mamas MA, et al. Factors associated with racial and ethnic diversity among heart failure trial participants: a systematic bibliometric review. Circ Heart Fail. 2022;15(3):e008685.PubMedCrossRef
59.
Breathett K, Sims M, Gross M, Jackson EA, Jones EJ, Navas-Acien A, et al. Cardiovascular health in American Indians and Alaska Natives: a scientific statement from the American Heart Association. Circulation. 2020;141(25):e948–59.PubMedPubMedCentralCrossRef
60.
Whitelaw S, Sullivan K, Eliya Y, Alruwayeh M, Thabane L, Yancy CW, et al. Trial characteristics associated with under-enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review. Eur J Heart Fail. 2021;23(1):15–24.PubMedCrossRef
61.
Jin X, Chandramouli C, Allocco B, Gong E, Lam CSP, Yan LL. Women’s participation in cardiovascular clinical trials from 2010 to 2017. Circulation. 2020;141(7):540–8.PubMedCrossRef
62.
Hong SJ, Lee YJ, Lee SJ, Hong BK, Kang WC, Lee JY, et al. Treat-to-target or high-intensity statin in patients with coronary artery disease: a randomized clinical trial. JAMA. 2023;329(13):1078–87.PubMedPubMedCentralCrossRef
63.
Khan MS, Shahid I, Siddiqi TJ, Khan SU, Warraich HJ, Greene SJ, et al. Ten-year trends in enrollment of women and minorities in pivotal trials supporting recent US Food and Drug Administration approval of novel cardiometabolic drugs. J Am Heart Assoc. 2020;9(11):e015594.PubMedPubMedCentralCrossRef
64.
Khan SU, Khan MZ, Raghu Subramanian C, Riaz H, Khan MU, Lone AN, et al. Participation of women and older participants in randomized clinical trials of lipid-lowering therapies: a systematic review. JAMA Netw Open. 2020;3(5):e205202.PubMedPubMedCentralCrossRef
65.
Gong IY, Tan NS, Ali SH, Lebovic G, Mamdani M, Goodman SG, et al. Temporal trends of women enrollment in major cardiovascular randomized clinical trials. Can J Cardiol. 2019;35(5):653–60.PubMedCrossRef
66.
Hong SJ, Lee YJ, Hong MK. Treating coronary artery disease with treat-to-target or high-intensity statin-reply. JAMA. 2023;330(5):471.PubMedCrossRef
67.
Mentz RJ, Anstrom KJ, Eisenstein EL, Sapp S, Greene SJ, Morgan S, et al. Effect of Torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial. JAMA. 2023;329(3):214–23.PubMedPubMedCentralCrossRef
68.
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539–48.PubMedCrossRef
69.
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–20.PubMedCrossRef
70.
Jones WS, Mulder H, Wruck LM, Pencina MJ, Kripalani S, Munoz D, et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med. 2021;384(21):1981–90.PubMedPubMedCentralCrossRef
71.
Pina IL, Jimenez S, Lewis EF, Morris AA, Onwuanyi A, Tam E, et al. Race and ethnicity in heart failure: JACC Focus Seminar 8/9. J Am Coll Cardiol. 2021;78(25):2589–98.PubMed
72.
Sarraju A, Valencia A, Knowles JW, Maron DJ, Rodriguez F. Diverse racial/ethnic group underreporting and underrepresentation in high-impact cholesterol treatment trials. Circulation. 2021;143(24):2409–11.PubMedPubMedCentralCrossRef
73.
Nunes JC, Rice EN, Stafford RS, Lewis EF, Wang PJ. Underrepresentation of ethnic and racial minorities in atrial fibrillation clinical trials. Circ Arrhythm Electrophysiol. 2021;14(12):e010452.PubMedCrossRef
74.
Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321(13):1261–74.PubMedPubMedCentralCrossRef
75.
Nissen SE, Menon V, Nicholls SJ, Brennan D, Laffin L, Ridker P, et al. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. JAMA. 2023;330(2):131–40.PubMedPubMedCentralCrossRef
76.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22.PubMedCrossRef
77.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–107.PubMedCrossRef
78.
Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662.PubMedPubMedCentralCrossRef
79.
Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195–203.PubMedCrossRef
80.
Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in Patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–47.PubMedCrossRef
81.
National Institutes of Health Revitalization Act of 1993: clinical research equity regarding women and minorities, (1993).
82.
Bernard MA, Clayton JA, Lauer MS. Inclusion across the lifespan: NIH policy for clinical research. JAMA. 2018;320(15):1535–6.PubMedCrossRef
83.
Sullivan LT 2nd, Randolph T, Merrill P, Jackson LR 2nd, Egwim C, Starks MA, et al. Representation of black patients in randomized clinical trials of heart failure with reduced ejection fraction. Am Heart J. 2018;197:43–52.PubMedCrossRef
84.
Reza N, Tahhan AS, Mahmud N, DeFilippis EM, Alrohaibani A, Vaduganathan M, et al. Representation of women authors in International Heart Failure Guidelines and Contemporary Clinical Trials. Circ Heart Fail. 2020;13(8):e006605.PubMedPubMedCentralCrossRef
85.
Denby KJ, Szpakowski N, Silver J, Walsh MN, Nissen S, Cho L. Representation of Women in cardiovascular clinical trial leadership. JAMA Intern Med. 2020;180(10):1382–3.PubMedPubMedCentralCrossRef
86.
Egwim CC, Rucker AJ, Madut DC, Chery GS, Sullivan LT 2nd, Jackson LR 2nd, et al. Research participation of a professional organization in clinical trials: the Association of Black cardiologists Clinical Trial Investigator Identification Project. J Natl Med Assoc. 2019;111(2):122–33.PubMed
87.
Coakley M, Fadiran EO, Parrish LJ, Griffith RA, Weiss E, Carter C. Dialogues on diversifying clinical trials: successful strategies for engaging women and minorities in clinical trials. J Womens Health (Larchmt). 2012;21(7):713–6.PubMedCrossRef
88.
Davis TC, Arnold CL, Mills G, Miele L. A qualitative study exploring barriers and facilitators of enrolling underrepresented populations in clinical trials and biobanking. Front Cell Dev Biol. 2019;7:74.PubMedPubMedCentralCrossRef
89.
Clark LT, Watkins L, Pina IL, Elmer M, Akinboboye O, Gorham M, et al. Increasing diversity in clinical trials: overcoming critical barriers. Curr Probl Cardiol. 2019;44(5):148–72.PubMedCrossRef
90.
Meng J, McLaughlin M, Pariera K, Murphy S. A comparison between caucasians and african americans in willingness to participate in cancer clinical trials: the roles of knowledge, distrust, information sources, and religiosity. J Health Commun. 2016;21(6):669–77.PubMedCrossRef
91.
Harrison JM, Jung M, Lennie TA, Moser DK, Smith DG, Dunbar SB, et al. Refusal to participate in heart failure studies: do age and gender matter? J Clin Nurs. 2016;25(7–8):983–91.PubMedPubMedCentralCrossRef
92.
Borno H, Siegel A, Ryan C. The problem of representativeness of clinical trial participants: understanding the role of hidden costs. J Health Serv Res Policy. 2016;21(3):145–6.PubMedCrossRef
93.
Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. J Natl Cancer Inst. 2019;111(3):245–55.PubMedPubMedCentralCrossRef
94.
Unger JM, Hershman DL, Albain KS, Moinpour CM, Petersen JA, Burg K, et al. Patient income level and cancer clinical trial participation. J Clin Oncol. 2013;31(5):536–42.PubMedPubMedCentralCrossRef
95.
Cox E, Alsalloum MA, Vander Schaaf M, Alfehaid AS, Alnewais ME, Weeda ER. Characteristics of United States counties in which heart failure clinical trials of pharmacotherapy were conducted. Circ Heart Fail. 2023;16(7):e010449.PubMedCrossRef
96.
Lindberg F, Lund LH, Benson L, Schrage B, Edner M, Dahlström U, et al. Patient profile and outcomes associated with follow-up in specialty vs. primary care in heart failure. ESC Heart Fail. 2022;9(2):822–33.PubMedPubMedCentralCrossRef
97.
Shore S, Basu T, Kamdar N, Brady P, Birati E, Hummel SL, et al. Use and out-of-pocket cost of sacubitril-valsartan in patients with heart failure. J Am Heart Assoc. 2022;11(17):e023950.PubMedPubMedCentralCrossRef
98.
Salata BM, Sterling MR, Beecy AN, Ullal AV, Jones EC, Horn EM, et al. Discharge processes and 30-day readmission rates of patients hospitalized for heart failure on general medicine and cardiology services. Am J Cardiol. 2018;121(9):1076–80.PubMedPubMedCentralCrossRef
99.
Selim AM, Mazurek JA, Iqbal M, Wang D, Negassa A, Zolty R. Mortality and readmission rates in patients hospitalized for acute decompensated heart failure: a comparison between cardiology and general-medicine service outcomes in an underserved population. Clin Cardiol. 2015;38(3):131–8.PubMedPubMedCentralCrossRef
100.
Jong P, Gong Y, Liu PP, Austin PC, Lee DS, Tu JV. Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists. Circulation. 2003;108(2):184–91.PubMedCrossRef
101.
Masters J, Morton G, Anton I, Szymanski J, Greenwood E, Grogono J, et al. Specialist intervention is associated with improved patient outcomes in patients with decompensated heart failure: evaluation of the impact of a multidisciplinary inpatient heart failure team. Open Heart. 2017;4(1):e000547.PubMedCentralCrossRef
102.
Perino AC, Fan J, Schmitt SK, Askari M, Kaiser DW, Deshmukh A, et al. Treating specialty and outcomes in newly diagnosed atrial fibrillation: from the TREAT-AF Study. J Am Coll Cardiol. 2017;70(1):78–86.PubMedPubMedCentralCrossRef
103.
Hawkins NM, Scheuermeyer FX, Youngson E, Sandhu RK, Ezekowitz JA, Kaul P, et al. Impact of cardiology follow-up care on treatment and outcomes of patients with new atrial fibrillation discharged from the emergency department. Europace. 2020;22(5):695–703.PubMedCrossRef
104.
Breathett K, Liu WG, Allen LA, Daugherty SL, Blair IV, Jones J, et al. African Americans are less likely to receive care by a cardiologist during an intensive care unit admission for heart failure. JACC Heart Fail. 2018;6(5):413–20.PubMedPubMedCentralCrossRef
105.
Eberly LA, Richterman A, Beckett AG, Wispelwey B, Marsh RH, Cleveland Manchanda EC, et al. Identification of racial inequities in access to specialized inpatient heart failure care at an academic medical center. Circ Heart Fail. 2019;12(11):e006214.PubMedPubMedCentralCrossRef
106.
Cook NL, Ayanian JZ, Orav EJ, Hicks LS. Differences in specialist consultations for cardiovascular disease by race, ethnicity, gender, insurance status, and site of primary care. Circulation. 2009;119(18):2463–70.PubMedCrossRef
107.
Ehrmann Feldman D, Xiao Y, Bernatsky S, Haggerty J, Leffondre K, Tousignant P, et al. Consultation with cardiologists for persons with new-onset chronic heart failure: a population-based study. Can J Cardiol. 2009;25(12):690–4.PubMedCrossRef
108.
Joshi AA, Lerman JB, Sajja AP, Dahiya G, Gokhale AV, Dey AK, et al. Sex-based differences in left ventricular assist device utilization: insights from the Nationwide Inpatient Sample 2004 to 2016. Circ Heart Fail. 2019;12(9):e006082.PubMedCrossRef
109.
Motairek I, Chen Z, Makhlouf MHE, Deo S, Salerno P, Mentias A, et al. Mapping geographic proximity to cardiologists across the United States. Circ Cardiovasc Qual Outcomes. 2023;e010133.
110.
111.
O’Neal WT, Sandesara PB, Claxton JS, MacLehose RF, Chen LY, Bengtson LGS, et al. Influence of sociodemographic factors and provider specialty on anticoagulation prescription fill patterns and outcomes in atrial fibrillation. Am J Cardiol. 2018;122(3):388–94.PubMedPubMedCentralCrossRef
112.
Abdel-Qadir H, Akioyamen LE, Fang J, Pang A, Ha ACT, Jackevicius CA, et al. Association of Neighborhood-level material deprivation with atrial fibrillation care in a single-payer health care system: a population-based cohort study. Circulation. 2022;146(3):159–71.PubMedPubMedCentralCrossRef
113.
Mathews L, Ding N, Sang Y, Loehr LR, Shin JI, Punjabi NM, et al. Racial differences in trends and prognosis of guideline-directed medical therapy for heart failure with reduced ejection fraction: the Atherosclerosis Risk in Communities (ARIC) Surveillance Study. J Racial Ethn Health Disparities. 2023;10(1):118–29.PubMedCrossRef
114.
Lamprea-Montealegre JA, Madden E, Tummalapalli SL, Peralta C, Neilands TB, Garcia PK, et al. Association of race and ethnicity with prescription of SGLT2 inhibitors and GLP1 receptor agonists among patients with type 2 diabetes in the Veterans Health Administration System. JAMA. 2022;328(9):861–71.PubMedPubMedCentralCrossRef
115.
Sangaralingham LR, Sangaralingham SJ, Shah ND, Yao X, Dunlay SM. Adoption of sacubitril/valsartan for the management of patients with heart failure. Circ Heart Fail. 2018;11(2):e004302.PubMedPubMedCentralCrossRef
116.
Essien UR, Magnani JW, Chen N, Gellad WF, Fine MJ, Hernandez I. Race/ethnicity and sex-related differences in direct oral anticoagulant initiation in newly diagnosed atrial fibrillation: a retrospective study of medicare data. J Natl Med Assoc. 2020;112(1):103–8.PubMed
117.
Wilson DA, Boadu O, Jones AL, Kim N, Mor MK, Hausmann LRM, et al. Analysis of initiating anticoagulant therapy for atrial fibrillation among persons experiencing homelessness in the Veterans Affairs Health System. JAMA Netw Open. 2022;5(7):e2223815.PubMedPubMedCentralCrossRef
118.
Bhave PD, Lu X, Girotra S, Kamel H, Vaughan Sarrazin MS. Race- and sex-related differences in care for patients newly diagnosed with atrial fibrillation. Heart Rhythm. 2015;12(7):1406–12.PubMedPubMedCentralCrossRef
119.
Golwala H, Jackson LR, Simon DN, Piccini JP, Gersh B, Go AS, et al. Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. Am Heart J. 2016;174:29–36.PubMedCrossRef
120.
Eberly LA, Garg L, Yang L, Markman TM, Nathan AS, Eneanya ND, et al. Racial/ethnic and socioeconomic disparities in management of incident paroxysmal atrial fibrillation. JAMA Netw Open. 2021;4(2):e210247.PubMedPubMedCentralCrossRef
121.
Schroff P, Gamboa CM, Durant RW, Oikeh A, Richman JS, Safford MM. Vulnerabilities to health disparities and statin use in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. J Am Heart Assoc. 2017;6(9).
122.
Colvin CL, Poudel B, Bress AP, Derington CG, King JB, Wen Y, et al. Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction. J Clin Lipidol. 2021;15(5):665–73.PubMedCrossRef
123.
Derington CG, Colantonio LD, Herrick JS, Cook J, King JB, Rosenson RS, et al. Factors associated with PCSK9 inhibitor initiation among US veterans. J Am Heart Assoc. 2021;10(8):e019254.PubMedPubMedCentralCrossRef
124.
Sandhu AT, Heidenreich PA. The affordability of guideline-directed medical therapy: cost sharing is a critical barrier to therapy adoption. Circulation. 2021;143(11):1073–5.PubMedPubMedCentralCrossRef
125.
Ton IT, Moon J, Sengul A, Mody FV, Rahman T, Han JK, et al. Evidence-based cardiovascular disease medicines’ availability in low-cost generic drug programs in the United States : a cross-sectional study. Ann Intern Med. 2023;176(9):1190–9.PubMedCrossRef
126.
127.
Faridi KF, Dayoub EJ, Ross JS, Dhruva SS, Ahmad T, Desai NR. Medicare coverage and out-of-pocket costs of quadruple drug therapy for heart failure. J Am Coll Cardiol. 2022;79(25):2516–25.PubMedCrossRef
128.
Ozaki AF, Krumholz HM, Mody FV, Tran TT, Le QT, Yokota M, et al. Prior authorization, copayments, and utilization of sacubitril/valsartan in medicare and commercial plans in patients with heart failure with reduced ejection fraction. Circ Cardiovasc Qual Outcomes. 2021;14(9):e007665.PubMedCrossRef
129.
Wang SY, Valero-Elizondo J, Ali HJ, Pandey A, Cainzos-Achirica M, Krumholz HM, et al. Out-of-pocket annual health expenditures and financial toxicity from healthcare costs in patients with heart failure in the United States. J Am Heart Assoc. 2021;10(14):e022164.PubMedPubMedCentralCrossRef
130.
131.
Wallace J, Lollo A, Duchowny KA, Lavallee M, Ndumele CD. Disparities in health care spending and utilization among Black and White Medicaid enrollees. JAMA Health Forum. 2022;3(6):e221398.PubMedPubMedCentralCrossRef
132.
Ali HR, Valero-Elizondo J, Wang SY, Cainzos-Achirica M, Bhimaraj A, Khan SU, et al. Subjective financial hardship due to medical bills among patients with heart failure in the United States: the 2014–2018 Medical Expenditure Panel Survey. J Card Fail. 2022;28(9):1424–33.PubMedCrossRef
133.
Tarn DM, Shih KJ, Schwartz JB. Reasons for nonadherence to the direct oral anticoagulant apixaban for atrial fibrillation. J Am Geriatr Soc. 2021;69(12):3683–7.PubMedPubMedCentralCrossRef
134.
Osborn CY, Kripalani S, Goggins KM, Wallston KA. Financial strain is associated with medication nonadherence and worse self-rated health among cardiovascular patients. J Health Care Poor Underserved. 2017;28(1):499–513.PubMedPubMedCentralCrossRef
135.
Essien UR, Singh B, Swabe G, Johnson AE, Eberly LA, Wadhera RK, et al. Association of prescription co-payment with adherence to glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor therapies in patients with heart failure and diabetes. JAMA Netw Open. 2023;6(6):e2316290.PubMedPubMedCentralCrossRef
136.
Johnson AE, Swabe GM, Addison D, Essien UR, Breathett K, Brewer LC, et al. Relation of household income to access and adherence to combination sacubitril/valsartan in heart failure: a retrospective analysis of commercially insured patients. Circ Cardiovasc Qual Outcomes. 2022;15(7):e009179.PubMedPubMedCentralCrossRef
137.
Appolon G, Tang S, Gabriel N, Morales J, Berenbrok LA, Guo J, et al. Association between redlining and spatial access to pharmacies. JAMA Netw Open. 2023;6(8):e2327315.PubMedPubMedCentralCrossRef
138.
Hawryluk M. The last drugstore: Rural America is losing its pharmacies. The Washington Post. 2021.
139.
Guadamuz JS, Alexander GC, Zenk SN, Kanter GP, Wilder JR, Qato DM. Access to pharmacies and pharmacy services in New York City, Los Angeles, Chicago, and Houston, 2015–2020. J Am Pharm Assoc (2003). 2021;61(6):e32-e41.
140.
Qato DM, Daviglus ML, Wilder J, Lee T, Qato D, Lambert B. “Pharmacy deserts” are prevalent in Chicago’s predominantly minority communities, raising medication access concerns. Health Aff (Millwood). 2014;33(11):1958–65.PubMedCrossRef
141.
Guadamuz JS, Wilder JR, Mouslim MC, Zenk SN, Alexander GC, Qato DM. Fewer pharmacies in Black and Hispanic/Latino neighborhoods compared with White or diverse neighborhoods, 2007–15. Health Aff (Millwood). 2021;40(5):802–11.PubMedCrossRef
142.
Amstislavski P, Matthews A, Sheffield S, Maroko AR, Weedon J. Medication deserts: survey of neighborhood disparities in availability of prescription medications. Int J Health Geogr. 2012;11:48.PubMedPubMedCentralCrossRef
143.
Luo J, Kulldorff M, Sarpatwari A, Pawar A, Kesselheim AS. Variation in prescription drug prices by retail pharmacy type: a national cross-sectional study. Ann Intern Med. 2019;171(9):605–11.PubMedCrossRef
144.
Reza N, Nayak A, Lewsey SC, DeFilippis EM. Representation matters: a call for inclusivity and equity in heart failure clinical trials. Eur Heart J Suppl. 2022;24(Suppl L):L45–8.PubMedPubMedCentralCrossRef
145.
Michos ED, Van Spall HGC. Increasing representation and diversity in cardiovascular clinical trial populations. Nat Rev Cardiol. 2021;18(8):537–8.PubMedCrossRef
146.
Assadpour E, Van Spall HGC. Pregnant and lactating women should be included in clinical trials for cardiovascular disease. Nat Med. 2023;29(8):1897–9.PubMedCrossRef
147.
Willard-Grace R, Dube K, Hessler D, O’Brien B, Earnest G, Gupta R, et al. Panel management, team culture, and worklife experience. Fam Syst Health. 2015;33(3):231–41.PubMedCrossRef
148.
Moise N, Cene CW, Tabak RG, Young DR, Mills KT, Essien UR, et al. Leveraging implementation science for cardiovascular health equity: a scientific statement from the American Heart Association. Circulation. 2022;146(19):e260–78.PubMedCrossRef
149.
Corbie-Smith G, Wiley-Cene C, Bess K, Young T, Dave G, Ellis K, et al. Heart Matters: a study protocol for a community based randomized trial aimed at reducing cardiovascular risk in a rural, African American community. BMC Public Health. 2018;18(1):938.PubMedPubMedCentralCrossRef
150.
Victor RG, Lynch K, Li N, Blyler C, Muhammad E, Handler J, et al. A cluster-randomized trial of blood-pressure reduction in Black barbershops. N Engl J Med. 2018;378(14):1291–301.PubMedPubMedCentralCrossRef
151.
152.
Chisholm-Burns MA, Kim Lee J, Spivey CA, Slack M, Herrier RN, Hall-Lipsy E, et al. US pharmacists’ effect as team members on patient care: systematic review and meta-analyses. Med Care. 2010;48(10):923–33.PubMedCrossRef
153.
Li N, Song JF, Zhang MZ, Lv XM, Hua HL, Chang YL. Impact of medication therapy management (MTM) service model on multi-morbidity (MMD) patients with hypertension: a pilot RCT. BMC Geriatr. 2023;23(1):10.PubMedPubMedCentralCrossRef
154.
155.
Belli HM, Chokshi SK, Hegde R, Troxel AB, Blecker S, Testa PA, et al. Implementation of a Behavioral Economics Electronic Health Record (BE-EHR) module to reduce overtreatment of diabetes in older adults. J Gen Intern Med. 2020;35(11):3254–61.PubMedPubMedCentralCrossRef
156.
Ahmadi A, Sorensen A, Villaflores CWA, Mafi JN, Vangala SS, Hofer IS, et al. Protocol for pragmatic randomised trial: integrating electronic health record-based behavioural economic “nudges” into the electronic health record to reduce preoperative testing for patients undergoing cataract surgery. BMJ Open. 2021;11(11):e049568.PubMedPubMedCentralCrossRef
157.
Ancker JS, Gossey JT, Nosal S, Xu C, Banerjee S, Wang Y, et al. Effect of an electronic health record “nudge” on opioid prescribing and electronic health record keystrokes in ambulatory care. J Gen Intern Med. 2021;36(2):430–7.PubMedCrossRef
158.
Meeker D, Knight TK, Friedberg MW, Linder JA, Goldstein NJ, Fox CR, et al. Nudging guideline-concordant antibiotic prescribing: a randomized clinical trial. JAMA Intern Med. 2014;174(3):425–31.PubMedPubMedCentralCrossRef
159.
Patel MS, Kurtzman GW, Kannan S, Small DS, Morris A, Honeywell S Jr, et al. Effect of an automated patient dashboard using active choice and peer comparison performance feedback to physicians on statin prescribing: the PRESCRIBE Cluster Randomized Clinical Trial. JAMA Netw Open. 2018;1(3):e180818.PubMedPubMedCentralCrossRef
160.
Blue L, Kranker K, Markovitz AR, Powell RE, Williams MV, Pu J, et al. Effects of the million hearts model on myocardial infarctions, strokes, and medicare spending: a randomized clinical trial. JAMA. 2023;330(15):1437–47.PubMedCrossRef
161.
Peterson GG, Pu J, Magid DJ, Barterian L, Kranker K, Barna M, et al. Effect of the million hearts cardiovascular disease risk reduction model on initiating and intensifying medications: a prespecified secondary analysis of a randomized clinical trial. JAMA Cardiol. 2021;6(9):1050–9.PubMedCrossRef
162.
Patel MR, Zhang G, Heisler M, Song PXK, Piette JD, Shi X, et al. Measurement and validation of the Comprehensive Score for Financial Toxicity (COST) in a population with diabetes. Diabetes Care. 2022;45(11):2535–43.PubMedPubMedCentralCrossRef
163.
Dine CJ, Masi D, Smith CD. Tools to help overcome barriers to cost-of-care conversations. Ann Intern Med. 2019;170(9_Suppl):S36–8.PubMedCrossRef
164.
Sloan CE, Ubel PA. The 7 Habits of highly effective cost-of-care conversations. Ann Intern Med. 2019;170(9_Suppl):S33–5.PubMedCrossRef
165.
166.
Hunter WG, Zafar SY, Hesson A, Davis JK, Kirby C, Barnett JA, et al. Discussing health care expenses in the oncology clinic: analysis of cost conversations in outpatient encounters. J Oncol Pract. 2017;13(11):e944–56.PubMedPubMedCentralCrossRef
167.
Brick DJ, Scherr KA, Ubel PA. The impact of cost conversations on the patient-physician relationship. Health Commun. 2019;34(1):65–73.PubMedCrossRef
168.
Altomare I, Irwin B, Zafar SY, Houck K, Maloney B, Greenup R, et al. Physician experience and attitudes toward addressing the cost of cancer care. J Oncol Pract. 2016;12(3):e281–8, 47–8.
169.
Shih YT, Chien CR. A review of cost communication in oncology: patient attitude, provider acceptance, and outcome assessment. Cancer. 2017;123(6):928–39.PubMedCrossRef
170.
Warsame R, Riordan L, Jenkins S, Lackore K, Pacyna J, Antiel R, et al. Responsibilities, strategies, and practice factors in clinical cost conversations: a US physician survey. J Gen Intern Med. 2020;35(7):1971–8.PubMedPubMedCentralCrossRef
171.
Meluch AL, Oglesby WH. Physician–patient communication regarding patients’ healthcare costs in the US: a systematic review of the literature. J Commun Healthc. 2015;8(2):151–60.CrossRef
172.
Rao BR, Speight CD, Allen LA, Halpern SD, Ko YA, Matlock DD, et al. Impact of financial considerations on willingness to take sacubitril/valsartan for heart failure. J Am Heart Assoc. 2022;11(12):e023789.PubMedPubMedCentralCrossRef
173.
Smith GH, Shore S, Allen LA, Markham DW, Mitchell AR, Moore M, et al. Discussing out-of-pocket costs with patients: shared decision making for sacubitril-valsartan in heart failure. J Am Heart Assoc. 2019;8(1):e010635.PubMedCrossRef
174.
Dusetzina SB, Besaw RJ, Whitmore CC, Mattingly TJ 2nd, Sinaiko AD, Keating NL, et al. Cost-Related medication nonadherence and desire for medication cost information among adults aged 65 years and older in the US in 2022. JAMA Netw Open. 2023;6(5):e2314211.PubMedPubMedCentralCrossRef
175.
Everson J, Whitmore CC, Mattingly TJ 2nd, Sinaiko AD, Dusetzina SB. Physician perspectives on implementation of real-time benefit tools: a qualitative study. Appl Clin Inform. 2022;13(5):1070–8.PubMedPubMedCentralCrossRef
176.
Sloan CE, Ubel PA. Patients want to talk about their out-of-pocket costs-can real-time benefit tools help? J Am Geriatr Soc. 2023;71(5):1365–8.PubMedCrossRef
177.
Centers for M, Medicaid Services DoH, Human S. Modernizing part d and medicare advantage to lower drug prices and reduce out-of-pocket expenses. Federal Register. 2019;84(100):23832–84.
178.
Sinaiko AD, Sloan CE, Soto MJ, Zhao O, Lin CT, Goss FR. Clinician response to patient medication prices displayed in the electronic health record. JAMA Intern Med. 2023.
179.
Desai SM, Chen AZ, Wang J, Chung WY, Stadelman J, Mahoney C, et al. Effects of real-time prescription benefit recommendations on patient out-of-pocket costs: a cluster randomized clinical trial. JAMA Intern Med. 2022;182(11):1129–37.PubMedPubMedCentralCrossRef
180.
Bhardwaj S, Merrey JW, Bishop MA, Yeh HC, Epstein JA. Associations between the use of a real-time benefit tool and measures related to prescription obtainment found in order type subgroups. J Am Pharm Assoc (2003). 2023.
181.
• Choudhry NK, Bykov K, Shrank WH, Toscano M, Rawlins WS, Reisman L, et al. Eliminating medication copayments reduces disparities in cardiovascular care. Health Aff (Millwood). 2014;33(5):863–70. In this trial, patients who were post-myocardial infarction were randomized to full prescription coverage (i.e., no copay) had significantly improved adherence compared to patients randomized to usual prescription coverage. Non-White patients in the full prescription coverage group also had 35% lower rates of major vascular events or revascularization and 70% lower total health care spending, while White patients saw no differences in these outcomes, suggesting that lower medication copays could reduce racial and ethnic disparities.PubMedCrossRef
182.
Choudhry NK, Fischer MA, Avorn JL, Lee JL, Schneeweiss S, Solomon DH, et al. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol. 2012;60(18):1817–24.PubMedCrossRef
183.
Choudhry NK, Fischer MA, Smith BF, Brill G, Girdish C, Matlin OS, et al. Five features of value-based insurance design plans were associated with higher rates of medication adherence. Health Aff (Millwood). 2014;33(3):493–501.PubMedCrossRef
184.
Glynn A, Hernandez I, Roberts ET. Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes. Health Serv Res. 2022;57(5):1136–44.PubMedPubMedCentralCrossRef
185.
Inflation Reduction Act of 2022, 117th Congress Sess. (2022).
186.
Schmittdiel JA, Marshall CJ, Wiley D, Chau CV, Trinacty CM, Wharam JF, et al. Opportunities to encourage mail order pharmacy delivery service use for diabetes prescriptions: a qualitative study. BMC Health Serv Res. 2019;19(1):422.PubMedPubMedCentralCrossRef
187.
Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142–7.PubMedCrossRef
Metadata
Title
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity
Authors
Krunal Amin
Garrett Bethel
Larry R. Jackson II
Utibe R. Essien
Caroline E. Sloan
Publication date
18-12-2023
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 12/2023
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-023-01180-5

Other articles of this Issue 12/2023

Current Atherosclerosis Reports 12/2023 Go to the issue

Review

Lipid Lowering Drugs in Acute Coronary Syndromes (ACS)

Review

Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia

Review

How to Handle Elevated Triglycerides: Life after PROMINENT

Review

Obesity and Dyslipidemia

Review

Caregiver Influences on Eating Behaviors in Children: An Opportunity for Preventing Obesity

Review

Sex differences in heart transplantations

2024 ESC Congress

Noise pollution dangerous for heart health

02-09-2024 Myocardial Infarction News

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

02-09-2024 Transcatheter Aortic Valve Implantation News

Antihypertensives: more effective at morning or night?

02-09-2024 Hypertension News

Low Lp(a) levels unlikely to increase the risk of diabetes

02-09-2024 Type 2 Diabetes News

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Electrocardiography Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

Obesity Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits